ETM1
MCID: ESS001
MIFTS: 59

Essential Tremor (ETM1) malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases

Aliases & Classifications for Essential Tremor

About this section

Aliases & Descriptions for Essential Tremor:

Name: Essential Tremor 52 11 48 25 49 27 50 39 13 68
Benign Essential Tremor 11 48 25
Tremor, Hereditary Essential, 1 48 68
Tremor, Hereditary Essential 1 70 27
Hereditary Essential Tremor 48 25
Familial Tremor 25 68
Etm1 48 70
Essential Tremor, Susceptibility to 12
 
Tremor Hereditary Essential, 1 48
Hereditary Essential Tremor 1 24
Tremor Familial Essential, 1 48
Essential Hereditary Tremor 11
Presenile Tremor Syndrome 48
Familial Essential Tremor 48
Shaky Hand Syndrome 11
Fet1 48

Characteristics:

HPO:

64
essential tremor:
Inheritance: autosomal dominant inheritance
Onset and clinical course: progressive

Classifications:



External Ids:

OMIM52 190300
Disease Ontology11 DOID:4990
ICD1030 G25.0
MeSH39 D020329
MedGen37 C1860861

Summaries for Essential Tremor

About this section
NINDS:49 Tremor is an unintentional, somewhat rhythmic, muscle movement involving to-and-fro movements (oscillations) of one or more parts of the body. Essential tremor (previously called benign essential tremor) is the most common form of abnormal tremor. (In some people, tremor is a symptom of a neurological disorder or appears as a side effect of certain drugs.)  Although it may be mild and nonprogressive in some people, in others the tremor is slowly progressive, starting on one side of the body but eventually affecting both sides. Hand tremor is most common but the head, arms, voice, tongue, legs, and trunk may also be involved. Hand tremor may cause problems with purposeful movements such as eating, writing, sewing, or shaving. Head tremor may be seen as a "yes-yes" or "no-no" motion. Essential tremor may be accompanied by mild gait disturbance. Heightened emotion, stress, fever, physical exhaustion, or low blood sugar may trigger tremors or increase their severity. There may be mild degeneration in the certain parts of the cerebellum in persons with essential tremor.  Onset is most common after age 40, although symptoms can appear at any age. Children of a parent who has essential tremor have up to a 50 percent chance of inheriting the condition. Essential tremor is not associated with any known pathology.

MalaCards based summary: Essential Tremor, also known as benign essential tremor, is related to personality disorder and hereditary essential tremor 5, and has symptoms including essential and other specified forms of tremor, essential and other specified forms of tremor and tremor. An important gene associated with Essential Tremor is DRD3 (Dopamine Receptor D3), and among its related pathways are Alpha-synuclein signaling and Neuroscience. The drugs propranolol and propranolol hydrochloride have been mentioned in the context of this disorder. Affiliated tissues include brain, cerebellum and tongue, and related mouse phenotypes are behavior/neurological and nervous system.

Disease Ontology:11 A movement disorder that causes involuntary tremors, especially in the hands. It occurs alone without other neurological signs and symptoms.

Genetics Home Reference:25 Essential tremor is a movement disorder that causes involuntary, rhythmic shaking (tremor), especially in the hands. It is distinguished from tremor that results from other disorders or known causes, such as Parkinson disease or head trauma. Essential tremor usually occurs alone, without other neurological signs or symptoms. However, some experts think that essential tremor can include additional features, such as mild balance problems.

NIH Rare Diseases:48 Essential tremor is the most common movement disorder.  it is characterized by involuntary and rhythmic shaking (tremor), especially in the hands, without any other signs or symptoms. it is distinguished from tremor that results from other disorders or known causes, such as tremors seen with parkinson disease or head trauma. most cases of essential tremor are hereditary. there are five forms of essential tremor that are based on different genetic causes. several genes as well as lifestyle and environmental factors likely play a role in a person's risk of developing this complex condition. in mild cases, treatment may not be necessary. in cases where symptoms interfere with daily living, medications may help to relieve symptoms.      last updated: 9/12/2014

OMIM:52 Essential tremor may be the most common human movement disorder. The main feature of essential tremor is postural... (190300) more...

UniProtKB/Swiss-Prot:70 Tremor, hereditary essential 1: A common movement disorder mainly characterized by postural tremor of the arms. Head, legs, trunk, voice, jaw, and facial muscles also may be involved. The condition can be aggravated by emotions, hunger, fatigue and temperature extremes, and may cause a functional disability or even incapacitation. Inheritance is autosomal dominant.

Wikipedia:71 Essential tremor (ET, also referred to as benign tremor, familial tremor, or idiopathic tremor) is the... more...

Related Diseases for Essential Tremor

About this section

Diseases in the Tremor family:

Tremor, Hereditary Essential, 2 essential tremor
Tremor, Hereditary Essential, 3 Tremor, Hereditary Essential, 4
Hereditary Essential Tremor 5

Diseases related to Essential Tremor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 60)
idRelated DiseaseScoreTop Affiliating Genes
1personality disorder29.2DRD3, FMR1, SLC6A3, SNCA
2hereditary essential tremor 512.0
3sensorineural hearing loss-early graying-essential tremor syndrome12.0
4tremor11.6
5mental retardation, autosomal recessive 4811.0
6tremor, hereditary essential, 411.0
7tremor, nystagmus, and duodenal ulcer11.0
8nephronophthisis-like nephropathy 110.8
9dystonia10.2
10pyromania10.1DRD3, SLC6A3
11ceroid lipofuscinosis, neuronal, 110.1LRRK2, SNCA
12lethal congenital contracture syndrome 810.1LRRK2, SNCA
13spink1-related hereditary pancreatitis10.1LRRK2, SNCA
14thrombosis10.1LRRK2, SNCA
15lower gum cancer10.1LRRK2, SLC6A3, SNCA
16cervical dystonia10.0
17cervicitis10.0
18ovarian mucinous adenocarcinoma10.0SLC1A2, SLC6A3, SNCA
19meier-gorlin syndrome 510.0LRRK2, SLC6A3, SNCA
20cardiomyopathy, dilated, 1u10.0FUS, LRRK2, SNCA
21trichothiodystrophy 3, photosensitive10.0HTRA2, LRRK2, SNCA
22autism 1910.0LRRK2, SLC6A3, SNCA
23coenzyme q10 deficiency, primary, 110.0LRRK2, SLC6A3, SNCA
24gallbladder adenoma10.0LRRK2, SLC6A3, SNCA
25ataxia10.0
26hemochromatosis, type 2a9.9DRD3, LRRK2, SLC6A3, SNCA
27riedel's fibrosing thyroiditis9.9LRRK2, SNCA
28eumycotic mycetoma9.9FUS, LRRK2, SLC6A3, SNCA
29substance-induced psychosis9.9LRRK2, SLC6A3, SNCA
30multiple system atrophy9.9
31restless legs syndrome9.9
32dementia9.9
33neuronitis9.9
34epithelioid type angiomyolipoma9.9LRRK2, SLC6A3, SNCA
35transient neonatal myasthenia gravis9.9DNAJC13, LRRK2, SNCA
36sarcoma9.8
37cerebritis9.8
38cavernous hemangioma9.8DRD3, FMR1, LRRK2, SLC6A3, SNCA
39cerebellar ataxia9.6
40alzheimer disease9.6
41obsessive-compulsive disorder9.6
42hereditary ataxia9.6
43hydrocephalus9.6
44apraxia9.6
45obsessive-compulsive personality disorder9.6
46hypothyroidism9.6
47normal pressure hydrocephalus9.6
48epilepsy9.6
49klinefelter's syndrome9.6
50lateral sclerosis9.6

Graphical network of the top 20 diseases related to Essential Tremor:



Diseases related to essential tremor

Symptoms & Phenotypes for Essential Tremor

About this section

Symptoms by clinical synopsis from OMIM:

190300

Clinical features from OMIM:

190300

Human phenotypes related to Essential Tremor:

 64
id Description HPO Frequency HPO Source Accession
1 dysarthria64 HP:0001260
2 postural tremor64 HP:0002174
3 hand tremor64 HP:0002378

UMLS symptoms related to Essential Tremor:


essential and other specified forms of tremor, tremor, senile tremor, action tremor, physiological tremor, tremor nec in icd9cm_2014

MGI Mouse Phenotypes related to Essential Tremor according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053868.3DRD3, FMR1, HTRA2, LRRK2, SLC1A2, SLC6A3
2MP:00036317.6DRD3, FMR1, HTRA2, LRRK2, SLC1A2, SLC6A3

Drugs & Therapeutics for Essential Tremor

About this section

Drugs for Essential Tremor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 164)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DopamineapprovedPhase 4, Phase 3383651-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
2
Pregabalinapproved, illicit, investigationalPhase 4361148553-50-85486971
Synonyms:
(3S)-3-(aminomethyl)-5-methylhexanoic acid
(R-)-3-isobutyl GABA
(S)-3-(Aminomethyl)-5-methylhexanoic acid
(S)-3-Isobutyl gaba
(S+)-3-isobutyl GABA
121GE001
148553-50-8
3-Isobutyl gaba
3-isobutyl GABA
AC-1158
AC1NUP03
AKOS005145504
C080245
C8H17NO2
CHEBI:236161
CHEMBL1059
CI 1008
CI-1008
CID5486971
 
D02716
DB00230
FT-0080911
HSDB 7530
LS-75191
Lyrica
Lyrica (TN)
MolPort-000-861-733
PD 144723
PD-144723
Pregabalin
Pregabalin (JAN/USAN/INN)
Pregabalin [USAN]
Pregablin
S-(+)-3-isobutylgaba
S1731_Selleck
SBB062901
TL8001062
TOS-BB-0910
UNII-55JG375S6M
3
AcetylcholineapprovedPhase 4, Phase 3, Phase 280551-84-3187
Synonyms:
ACh
Acetyl choline ion
Acetylcholine Chloride
Acetylcholine cation
 
Acetylcholinium: acetyl-Choline
Choline acetate
Choline acetate (ester)
O-Acetylcholine
acetylcholine chloride
4
Memantineapproved, investigationalPhase 418119982-08-24054
Synonyms:
1,3-Dimethyl-5-adamantanamine
1-Amino-3,5-dimethyladamantane
19982-08-2
3,5-Dimethyl-1-adamantanamine
3,5-Dimethyl-1-adamantylamine
3,5-Dimethyl-1-aminoadamantane
3,5-Dimethyladamantan-1-ylamine
3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine
3,5-dimethyladamantan-1-amine
3,5-dimethyltricyclo[3.3.1.1~3,7~]decan-1-amine
41100-52-1 (Hydrochloride)
51052-62-1
AB00053600
AC1L1HB7
AKOS000113995
BBL000737
BPBio1_001117
BPBio1_001270
BSPBio_001015
Biomol-NT_000209
C13736
CBMicro_020348
CHEBI:152523
CHEMBL807
CID4054
D08174
DB01043
DMAA
DivK1c_000068
EU-0053634
Ebixa
Exiba
Exiba (TN)
HMS500D10
HSDB 7327
IDI1_000068
KBio1_000068
KBio2_001087
KBio2_003655
 
KBio2_006223
KBio3_001926
KBioGR_001543
KBioSS_001087
LS-157051
Lopac0_000861
Memantin
Memantina
Memantina [INN-Spanish]
Memantine
Memantine (INN)
Memantine HCL
Memantine Hydrochloride
Memantine [INN:BAN]
Memantine [INN]
Memantinum
Memantinum [INN-Latin]
MolPort-002-041-858
NCGC00015705-05
NCGC00024782-02
NCGC00024782-03
NINDS_000068
Namenda
Oprea1_480562
Prestwick0_000978
Prestwick1_000978
Prestwick2_000978
Prestwick3_000978
SPBio_001456
SPBio_002926
ST057652
STK520682
Spectrum2_001408
Spectrum3_000923
Spectrum4_001022
Spectrum5_001355
Spectrum_000607
UNII-W8O17SJF3T
ZERO/006024
memantine
5
Propranololapproved, investigationalPhase 4228525-66-64946
Synonyms:
(+-)-Propranolol
(1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol
(R)-(+)-propranolol
(S)-(-)-PROPRANOLOL
1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol
1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane
1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol
1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol
1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol
1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol
1-Isopropylamino-3-(1-naphthyloxy)-2-propanol
1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol
13013-17-7
2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)- (9CI)
2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)- (9CI)
3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol
4199-09-1
4199-10-4
525-66-6
AB00053537
AC1L1JA4
AC1Q1QBV
AC1Q1QC0
AKOS000588816
AY 64043
AY-20694
Anaprilin
Anapriline
Angilol
Apsolol
Avlocardyl
BPBio1_001040
BRD-A10070317-003-06-9
BSPBio_000944
BSPBio_002682
Bedranol
Beprane
Berkolol
Beta Neg
Beta-Neg
Beta-Propranolol
Beta-Tablinen
Beta-Timelets
Betachron
Betadren
Betalong
Bio-0732
Bio1_000367
Bio1_000856
Bio1_001345
C07407
C16H21NO2
CBDivE_006180
CCRIS 3082
CHEBI:8499
CHEMBL27
CID4946
Cardinol
Caridolol
Corpendol
D,L-Propranolol
D08443
DB00571
DL-Propranolol hydrochloride
Deralin
DivK1c_000023
Dl-Propranolol Hydrochloride
Dociton
Duranol
EINECS 208-378-0
EINECS 235-867-6
Efektolol
Elbrol
Etalong
Euprovasin
Frekven
HMS2090L21
Herzbase
ICI 45520
IDI1_000023
INDERIDE-40/25
INDERIDE-80/25
Ikopal
Inderal
Inderal La
Inderal hydrochloride
Inderalici
Inderex
Inderide
Inderol
Indobloc
InnoPranXL
 
Innopran XL
Intermigran
KBio1_000023
KBio2_002515
KBio2_005083
KBio2_007651
KBio3_001766
KBio3_001902
KBio3_002993
KBioGR_001347
KBioGR_001684
KBioGR_002515
KBioSS_002523
Kemi
Kemi S
L000679
LS-122410
LS-184129
Lopac0_000896
Migrastat
MolPort-001-794-623
NCGC00015798-07
NCGC00024690-02
NCGC00024690-03
NINDS_000023
NSC91523
Naprilin
Obsidan
Obzidan
Oposim
Oprea1_304193
PDSP1_000767
PDSP1_001607
PDSP1_001608
PDSP2_000755
PDSP2_001591
PDSP2_001592
Prano-Puren
Pranolol
Prestwick0_000952
Prestwick1_000952
Prestwick2_000952
Prestwick3_000952
Pronovan
Propanalol
Propanix
Propanolol
Propanolol [INN-Spanish]
Prophylux
Propranalol
Propranolol
Propranolol (INN)
Propranolol (TN)
Propranolol Hcl
Propranolol Hcl Intensol
Propranolol Hydrochloride
Propranolol [INN:BAN]
Propranololo
Propranololo [DCIT]
Propranololum
Propranololum [INN-Latin]
Propranur
Proprasylyt
Pylapron
R,S-Propranolol Hydrochloride
Racemic propranolol
Rapynogen
Reducor
Reducor Line
Reducor line
SPBio_001361
SPBio_001658
SPBio_003093
STK735510
Sagittol
Sawatal
Servanolol
Sloprolol
Spectrum2_001301
Spectrum2_001699
Spectrum3_000883
Spectrum3_001071
Spectrum4_000974
Spectrum4_001222
Spectrum5_000751
Sumial
Tesnol
UNII-9Y8NXQ24VQ
b-Propranolol
beta-Propranolol
cMAP_000071
etalong
propranolol
propranololo
β-Propranolol
6Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 123689
7Central Nervous System DepressantsPhase 4, Phase 3, Phase 2, Phase 113403
8Dopamine AgentsPhase 4, Phase 33836
9Neurotransmitter AgentsPhase 4, Phase 3, Phase 2, Phase 118340
10Antiparkinson AgentsPhase 4, Phase 31574
11Adrenergic AntagonistsPhase 41573
12Adrenergic beta-AntagonistsPhase 41193
13Anti-Arrhythmia AgentsPhase 4, Phase 13093
14Vasodilator AgentsPhase 43543
15Adrenergic AgentsPhase 4, Phase 3, Phase 2, Phase 15352
16Botulinum ToxinsPhase 4, Phase 3, Phase 2697
17Antihypertensive AgentsPhase 4, Phase 14207
18Pharmaceutical SolutionsPhase 4, Phase 2, Phase 18192
19Cholinergic AgentsPhase 4, Phase 3, Phase 2, Phase 13992
20Anti-Anxiety AgentsPhase 4, Phase 11885
21AnalgesicsPhase 4, Phase 2, Phase 311733
22Excitatory Amino AcidsPhase 41362
23Tranquilizing AgentsPhase 4, Phase 14265
24Excitatory Amino Acid AntagonistsPhase 41347
25Psychotropic DrugsPhase 4, Phase 16430
26AnticonvulsantsPhase 4, Phase 3, Phase 2, Phase 12695
27Calcium, DietaryPhase 4, Phase 25713
28calcium channel blockersPhase 4, Phase 21985
29
IodinePhase 45707553-56-2807
Synonyms:
I2
Iode
Iodine-molecule
 
Iodio
Iodum
Jod
Jood
Tincture iodine
30cadexomer iodinePhase 4537
31CalamusNutraceuticalPhase 4459
32
Cocaineapproved, illicitPhase 351150-36-25760, 446220
Synonyms:
(-)-Cocaine
(-)-Cocaine base
(1R,2R,3S,5S)-2-(methoxycarbonyl)tropan-3-yl benzoate
(1R,2R,3S,5S)-2-Methoxycarbonyltropan-3-yl benzoate
(R)-Cocaine
(−)-cocaine
1-Cocaine
1i7z
1q72
2-Methyl-3beta-hydroxy-1alphah,5alphah-tropane-2beta-carboxylate benzoate (ester)
2-beta-Carbomethoxy-3-beta-benzoxytropane
2-beta-Tropanecarboxylic acid, 3-beta-hydroxy-, methyl ester, benzoate (ester)
2beta-Carbomethoxy-3beta-benzoxytropane
3-Tropanylbenzoate-2-carboxylic acid methyl ester
3beta-Hydroxy-2beta-tropanecarboxylic acid methyl ester benzoate (ester)
50-36-2
53-21-4 (hydrochloride)
610089_ALDRICH
610089_FLUKA
AC-16037
AC-20208
AC1L1EK2
AC1L1L2T
AC1L3U2D
AC1L9JBL
Allococaine
Allopseudococaine
Badrock
Bazooka
Benzoylethylecgonine
Benzoylmethylecgonine
Bernice
Bernice [Street Name]
Bernies
Beta-Cocain
Blast
Blizzard
Blow
Blow [Street Name]
Bouncing Powder
Bump
Burese
C" Carrie
C01416
C8912_SIGMA
CHEBI:27958
CID11779748
CID2826
CID446220
CID5760
COC
CPD-9776
Cabello
Candy
Carrie
Caviar
Cecil
Cecil [Street Name]
Charlie
Chicken Scratch
Cholly
Coca
Cocain
Cocaina
Cocaine
Cocaine (TN)
Cocaine (USP)
Cocaine Free Base
Cocaine [BAN]
Cocaine free base
Cocaine solution
Cocaine-M
Cocainum
Cocktail
Coke
Cola
Corine
Crack
Crack cocaine
D-pseudococaine
D00110
DB00907
DEA No. 9041
Dama Blanca
Dama blanca
Delcaine
Depsococaine
Dextrocaine
DivK1c_000975
Dust
EINECS 200-032-7
Ecgonine methyl ester benzoate
Ecgonine methyl ester benzoate solution
Ecgonine, methyl ester, benzoate (ester)
 
Eritroxilina
Erytroxylin
Flake
Flake [Street Name]
Flex
Florida Snow
Foo Foo
Freeze
G-Rock
Girl
Girl [Street Name]
Gold Dust
Gold dust
Gold dust [Street Name]
Goofball
Green Gold
Green gold
HSDB 6469
Happy Dust
Happy Powder
Happy Trails
Happy dust
Happy dust [Street Name]
Happy powder
Happy trails
Heaven
Hell
IDI1_000975
Isocaine
Isococain
Isococaine
Jam
KBio1_000975
Kibbles N' Bits
Kibbles n' Bits
Kokain
Kokan
Kokayeen
L-Cocain
L-Cocaine
L000836
LS-157759
Lady
Lady [Street Name]
Leaf
MLS002320697
Methyl 3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate
Methyl 3beta-hydroxy-1alphaH,5alphaH-tropane-2beta-carboxylate benzoate (ester)
Methyl Benzoylecgonine
Methyl [1R-(exo,exo)]-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate
Methyl benzoylecgonine
MolPort-002-535-520
MolPort-003-937-722
Moonrocks
NCGC00159467-02
NINDS_000975
Neurocaine
Nose candy
Pimp's Drug
Pimp's drug
Prime Time
Pseudoallococaine
Pseudococaine
Rock
Rock [Street Name]
SMR001338843
STOCK1N-68258
Sleighride
Snort
Snow
Snow (birds)
Star Dust
Star dust
Star-Spangled Powder
Star-spangled powder
Sugar
Sweet Stuff
Toke
Toot
Toot [Street Name]
Trails
UNII-I5Y540LHVR
White girl or lady
Yeyo
Zip
[1R-(Exo,exo)]-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid, methyl ester
beta-Cocain
cocaine
cocainum
d-Pseudococaine
l-Cocain
methyl (1S,4R,5R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate
methyl (3S,4R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate
methyl 3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate
nchembio.284-comp4
33
PhenylephrineapprovedPhase 3, Phase 145559-42-76041
Synonyms:
(-)-m-Hydroxy-alpha-(methylaminomethyl)benzyl alcohol
(-)-m-Hydroxy-α-(methylaminomethyl)benzyl alcohol
(R)-2-Hydroxy-2-(3-hydroxyphenyl)-N-methylethylamine
(R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol
1416-03-1
3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol
59-42-7
61-76-7 (hydrochloride)
AC1L1LO9
AC1Q40UF
AI3-02402
AK-Dilate
AK-Nefrin
Adrianol
Ah-Chew
Ak-Dilate
Ak-Nefrin
Ak-dilate
Ak-nefrin
Alcon Efrin
Alcon efrin
Alconefrin Nasal Drops 12
Alconefrin Nasal Drops 25
Alconefrin Nasal Drops 50
Alconefrin Nasal Spray 25
BIDD:GT0157
BSPBio_002420
Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, (R)- (9CI)
Biomydrin
C07441
CCRIS 8464
CHEBI:8093
CHEMBL1215
CID6041
Cyclomydril
D08365
DB00388
Dilatair
Dimetane
Dionephrine
DivK1c_000597
Doktors
Duration
EINECS 200-424-8
EINECS 215-810-1
Fenilefrina
Fenilefrina [INN-Spanish]
HSDB 3383
I-Phrine
IDI1_000597
Isophrim
Isophrin
Isopto Frin
KBio1_000597
KBio2_001581
KBio2_004149
KBio2_006717
KBio3_001640
KBioGR_001313
KBioSS_001581
L-Phenylephedrine
L-Phenylephrine
LS-43027
Lopac-P-6126
Lopac0_000920
M-Methylaminoethanolphenol
M-Oxedrine
M-Sympathol
M-Sympatol
M-Synephrine
 
Mesaton
Mesatone
Mesatonum
Metaoxedrin
Metaoxedrine
Metaoxedrinum
Metasympatol
Metasynephrine
Metsatonum
Mezaton
Minims Phenylephrine
MolPort-001-792-191
Mydfrin
NCGC00015825-01
NCGC00015825-02
NCGC00024257-03
NCGC00024257-05
NCGC00024257-06
NINDS_000597
Neo-Synephrine
Neo-Synephrine Nasal Drops
Neo-Synephrine Nasal Jelly
Neo-Synephrine Nasal Spray
Neo-Synephrine Pediatric Nasal Drops
Neofrin
Neophryn
Neosynephrine
Nostril
Nostril Spray Pump
Nostril Spray Pump Mild
Ocu-Phrin Sterile Eye Drops
Ocu-Phrin Sterile Ophthalmic Solution
Ocugestrin
P0395
PDSP1_001108
PDSP2_001092
Phenoptic
Phenylephrine
Phenylephrine (INN)
Phenylephrine Minims
Phenylephrine Minims (TN)
Phenylephrine [INN:BAN]
Phenylephrinum
Phenylephrinum [INN-Latin]
Prefrin
Prefrin Liquifilm
Pyracort D
R(-)-Mezaton
R(-)-Phenylephrine
Relief Eye Drops for Red Eyes
Rhinall
SPBio_001280
Spectrum2_001280
Spectrum3_000770
Spectrum4_000967
Spectrum5_001411
Spectrum_001101
Spersaphrine
Tannins, compds. with (R)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol
UNII-1WS297W6MV
Vicks Sinex
Visadron
l-(3-Hydroxyphenyl)-N-methylethanolamine
l-1-(m-Hydroxyphenyl)-2-methylaminoethanol
l-alpha-Hydroxy-beta-methylamino-3-hydroxy-L-ethylbenzene
l-m-Hydroxy-alpha-((methylamino)methyl)benzyl alcohol
m-Methylaminoethanolphenol
m-Oxedrine
m-Sympathol
m-Sympatol
m-Synephrine
phenylephrine
34
OxymetazolineapprovedPhase 3, Phase 14551491-59-44636
Synonyms:
1491-59-4
2-(4-Tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline
2-(4-tert-Butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline
3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethyl-6-tert-butyl-phenol
3-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol
3-[(4,5-dihydro-1H-Imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol
6-Tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
6-t-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
6-tert-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
6-tert-Butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol
AC-6370
AC1L1IM1
Afrin Cherry 12 Hour Nasal Spray
Afrin Extra Moisturizing 12 Hour Nasal Spray
Afrin Original 12 Hour Nasal Spray
Afrin Original 12 Hour Nose Drops
Afrin Original 12 Hour Pump Mist
Afrin Sinus 12 Hour Nasal Spray
BPBio1_000295
BPBio1_000419
BRD-K16195444-001-01-7
BRN 0886303
BSPBio_000267
BSPBio_002145
Biomol-NT_000161
C07363
CAS-151615
CHEBI:142520
CHEMBL762
CID4636
D010109
D08322
DB00935
DivK1c_000567
Dristan Long Lasting Mentholated Nasal Spray
Dristan Long Lasting Nasal Mist
Drixoral Nasal Solution
Duramist Plus Up To 12 Hour Nasal Decongestant Spray
EINECS 216-079-1
FT-0082560
Genasal Nasal Spray Up to 12 Hour Relief
H 990
HMS2089G03
HSDB 3143
Hazol
IDI1_000567
Iliadin
KBio1_000567
KBio2_001531
KBio2_004099
KBio2_006667
KBio3_001645
KBioGR_000908
KBioSS_001531
L000459
LS-104146
 
Lopac-O-2378
Lopac0_000903
MolPort-002-538-313
NCGC00015766-01
NCGC00015766-02
NCGC00015766-03
NCGC00015766-10
NCGC00022345-02
NCGC00022345-04
NCGC00022345-05
NCGC00022345-06
NINDS_000567
Nafrine
Nasal Relief 12 Hour Nasal Spray
Navasin
Navisin
Neo-Synephrine 12 Hour Spray
Nezeril
Nostrilla 12 Hour Nasal Decongestant
Operil (TN)
Oximetazolina
Oximetazolina [INN-Spanish]
Oximetazolinum
Oxylazine
Oxymetazolina
Oxymetazoline (INN)
Oxymetazoline [INN:BAN]
Oxymetazoline hydrochloride crystalline
Oxymetazolinum
Oxymetazolinum [INN-Latin]
Oxymethazoline
Oxymetozoline
Phenol, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl- (9CI)
Phenol, 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl- (7CI,8CI)
Prestwick0_000224
Prestwick1_000224
Prestwick2_000224
Prestwick3_000224
Rhinofrenol
Rhinolitan
SPBio_001095
SPBio_002188
Sinerol
Spectrum2_000998
Spectrum3_000533
Spectrum4_000464
Spectrum5_001114
Spectrum_001051
Tocris-1142
UNII-8VLN5B44ZY
Vicks Sinex 12 Hour Nasal Spray
Vicks Sinex 12 Hour Ultra Fine Mist for Sinus Relief
Visine L.R
Visine L.R.
nchembio705-11
oxymeta zoline
oxymetazoline
oxymetazoline hydrochloride crystalline
35
TopiramateapprovedPhase 324997240-79-45284627
Synonyms:
-D-fructopyranose deriv.
.beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate (9CI)
2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene) .beta.-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-36-D-fructo-pyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
2,3:4,5-Di- O -isopropylidene-(beta)-D-fructopyranose sulfamate
2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate
5H-Bis[1,3]dioxolo[4,5-b:4',5'-d]pyran, .beta.
97240-79-4
AKOS000424547
BIDD:GT0854
BIDD:PXR0127
BRN 5988957
BSPBio_002306
C052342
C07502
C12H21NO8S
CBChromo1_000352
CHEBI:129573
CHEMBL220492
CID5284627
CPD000466325
Cilag brand of topiramate
D00537
DB00273
Epitoma
Epitomax
HMS1922H06
HMS2051L09
HMS2093D20
HSDB 7531
Janssen brand of topiramate
KS-1122
KW-6485
LS-187392
LS-69764
MLS000759431
MLS001424070
McN 4853
McN-4853
MolPort-001-615-062
MolPort-002-885-869
NCGC00178714-01
 
Ortho brand of topiramate
RWJ 17021
RWJ-17021
RWJ-17021-000
S1438_Selleck
SAM001246601
SMR000466325
SPBio_000995
SPECTRUM1505801
STOCK1N-71037
Spectrum2_001128
T0575_SIGMA
TL8006021
TOR
TPM
Tipiramate
Tipiramate [French]
Tipiramato
Tipiramato [Spanish]
Topamac
Topamax
Topamax (TN)
Topamax Sprinkle
Topamax, Topiramate
Topimax
Topina
Topiramate
Topiramate (JAN/USAN/INN)
Topiramate (TPM)
Topiramate / Placebo
Topiramate [USAN:BAN:INN]
Topiramato
Topiramato [INN-Spanish]
Topiramatum
Topiramatum [INN-Latin]
Topiramic acid
Topomax
UNII-0H73WJJ391
USL-255
[(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate
beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate
beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, 1-sulfamate
topiramate
topiramate tablet
topiramatum [Latin]
36Neurotransmitter Uptake InhibitorsPhase 33521
37Anesthetics, LocalPhase 33492
38AnestheticsPhase 3, Phase 2, Phase 19596
39Vasoconstrictor AgentsPhase 32122
40Dopamine Uptake InhibitorsPhase 31331
41
Salmeterol xinafoatePhase 3, Phase 2, Phase 135994749-08-356801
Synonyms:
(+-)-4-Hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol 1-hydroxy-2-naphthoate (salt)
(+/-) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol xinafoate
1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-, 1-hydroxy-2-naphthalenecarboxylate (salt)
1-hydroxynaphthalene-2-carboxylic acid
2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol
89365-50-4 (Parent)
94749-08-3
AC1L1LPS
Arial
Asmerole
Beglan
Betamican
Bio-0096
C25H37NO4.C11H8O3
CHEMBL1082607
CID56801
D00687
Dilamax
EU-0101100
GR 33343 G
GR 33343X xinafoate
 
GR-33343 G
Inaspir
LS-94516
MLS001332577
MLS001332578
MolPort-003-850-218
NCGC00094372-01
NCGC00094372-02
NCGC00094372-03
NCGC00094372-04
S5068_SIGMA
SMR000875207
Salmetedur
Salmeterol 1-hydroxy-2-naphthoate
Salmeterol xinafoate (JAN/USAN)
Salmeterol xinafoate [USAN]
Serevent (TN)
Serevent Inhaler and Disks
Serevent diskus
UNII-6EW8Q962A5
Ultrabeta
salmeterol xinafoate
42Respiratory System AgentsPhase 3, Phase 2, Phase 14997
43Tiotropium BromidePhase 3, Phase 2, Phase 1337136310-93-5
44ParasympatholyticsPhase 3, Phase 2, Phase 11085
45incobotulinumtoxinAPhase 3, Phase 2662
46Hypnotics and SedativesPhase 2, Phase 3, Phase 12616
47AntioxidantsPhase 3, Phase 2, Phase 13050
48Botulinum Toxins, Type APhase 3, Phase 2657
49abobotulinumtoxinAPhase 3, Phase 2652
50onabotulinumtoxinAPhase 3, Phase 2652

Interventional clinical trials:

(show top 50)    (show all 204)
idNameStatusNCT IDPhase
1Validation of DaTscan for Detection of Parkinson Disease Related DisordersUnknown statusNCT02138682Phase 4
2A Pilot Clinical Trial Of Memantine for Essential TremorCompletedNCT00439699Phase 4
3Pregabalin in the Treatment of Essential TremorCompletedNCT00646451Phase 4
4Pregabalin (Lyrica) for the Treatment of Essential TremorCompletedNCT00584376Phase 4
5Propranolol and Botulinum Toxin for Essential Vocal TremorCompletedNCT02111369Phase 4
6RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR)CompletedNCT00998660Phase 4
7A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar SymptomsCompletedNCT00382967Phase 4
8Atlas Predicted DBS Settings in Essential TremorEnrolling by invitationNCT02678429Phase 4
9DaTSCAN Imaging in Aging and Neurodegenerative DiseaseEnrolling by invitationNCT01453127Phase 4
10Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity TremorUnknown statusNCT00724906Phase 3
11Novel Therapies for Essential TremorCompletedNCT00018564Phase 3
12A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in Treating Tremor of Unknown Cause.CompletedNCT00236496Phase 3
13Efficacy and Safety of F-18 FPCIT PET in Parkinson's Disease and Essential Tremor PatientsCompletedNCT00468078Phase 3
14Long-term Effect of Low Frequency Stimulation on Aspiration and Freezing of Gait in PD With STN DBSCompletedNCT02549859Phase 2, Phase 3
15Tiotropium and Salmeterol PK Study in COPD PatientsCompletedNCT00673478Phase 3
16Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential TremorRecruitingNCT02555982Phase 3
17Pre-lemniscal Radiation Deep Brain Stimulation for ETTerminatedNCT00634478Phase 2, Phase 3
18Efficacy of Pramipexole Extended Release in the Treatment of Essential TremorWithdrawnNCT01441284Phase 3
19Dexmedetomidine Effects on Microelectrode Recording in Deep Brain StimulationWithdrawnNCT00608231Phase 2, Phase 3
20A Safety/Efficacy Trial of Zonisamide for Essential TremorCompletedNCT00223743Phase 2
21Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential TremorCompletedNCT00598078Phase 2
22A Pilot Efficacy and Safety Study of ST101 in Essential TremorCompletedNCT01332695Phase 2
23A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential TremorCompletedNCT00524056Phase 2
24Octanol to Treat Essential TremorCompletedNCT00080366Phase 2
25Efficacy of Levetiracetam in Essential TremorCompletedNCT00620165Phase 1, Phase 2
26Double-Blind, Placebo Controlled Pilot Study of Octanoic Acid in Essential TremorCompletedNCT00848172Phase 1, Phase 2
27Evaluate SAGE-547 in Patients With Essential TremorCompletedNCT02277106Phase 2
28Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential TremorCompletedNCT00102596Phase 2
29Botulinum Toxin A to Treat Arm TremorCompletedNCT02207946Phase 2
30Effects of Octanoic Acid for Treatment of Essential Voice TremorCompletedNCT01864525Phase 1, Phase 2
31Effect of Alcohol on TremorsCompletedNCT00001925Phase 2
32Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02242266Phase 2
33Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder Administered Via the HandiHaler® 2 and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02242227Phase 2
34Salmeterol Inhalation Powder Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02238106Phase 2
35Botulinum Toxin Type A for Injection of Bilateral Upper Extremity Tremor in Patients With Essential Tremor Using Kinematic AssessmentRecruitingNCT02551848Phase 2
36A Study to Evaluate SAGE-217 in Subjects With Essential TremorRecruitingNCT02978781Phase 2
37Deep Brain Stimulation for Voice Tremor: Left, Right, or Both Hemispheres?RecruitingNCT02960243Phase 1, Phase 2
38Randomised Crossover Trial of Deep Brain Stimulation of Differential Posterior Subthalamic Area Regions in Parkinson's Disease and TremorRecruitingNCT01945567Phase 2
39Deep Brain Frameless Radiosurgery for Drug Resistant Invalidating Tremor. Dose Escalation Pilot StudyRecruitingNCT02585583Phase 2
40An Efficacy/Safety Study of Perampanel for Reducing Essential TremorActive, not recruitingNCT02668146Phase 2
41Use of Kinematic Assessment of Hand Tremor Pre- and Post- Treatment With Botulinum Toxin Type A in Essential Tremor and Parkinson DiseaseEnrolling by invitationNCT02427646Phase 2
42A Phase 2 RCT Study of CX-8998 for Essential TremorNot yet recruitingNCT03101241Phase 2
43A Study of T2000 in Essential TremorTerminatedNCT00321087Phase 2
44T2000 in Essential Tremor - Open Label ContinuationTerminatedNCT00655278Phase 2
45Octanoic Acid for Essential TremorCompletedNCT01468948Phase 1
461-Octanol to Treat Essential TremorCompletedNCT00016679Phase 1
471-Octanol to Treat Essential TremorCompletedNCT00001986Phase 1
48ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential TremorCompletedNCT02037217Phase 1
49ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential TremorCompletedNCT01304758Phase 1
50Magnetic Resonance (MR) Guided Functional Ultrasound-Neurosurgery for Movement DisordersCompletedNCT01698450Phase 1

Search NIH Clinical Center for Essential Tremor

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: essential tremor

Genetic Tests for Essential Tremor

About this section

Genetic tests related to Essential Tremor:

id Genetic test Affiliating Genes
1 Hereditary Essential Tremor 127 24 DRD3
2 Essential Tremor27

Anatomical Context for Essential Tremor

About this section

MalaCards organs/tissues related to Essential Tremor:

36
Brain, Cerebellum, Tongue, Cortex, Testes, Thalamus, Subthalamic nucleus

Publications for Essential Tremor

About this section

Articles related to Essential Tremor:

(show top 50)    (show all 697)
idTitleAuthorsYear
1
Coronal Transcranial Sonography and M-Mode Tremor Frequency Determination in Parkinson's Disease and Essential Tremor. (28426143)
2017
2
A data mining approach using cortical thickness for diagnosis and characterization of essential tremor. (28526878)
2017
3
Early Head Tremor in Essential Tremor: A Case Series and Commentary. (28373926)
2017
4
A computerized tablet system for evaluating treatment of essential tremor by magnetic resonance guided focused ultrasound. (28412948)
2017
5
A Network Model of Local Field Potential Activity in Essential Tremor and the Impact of Deep Brain Stimulation. (28068428)
2017
6
Efficacy of Fiber Tractography in the Stereotactic Surgery of the Thalamus for Patients with Essential Tremor. (28458383)
2017
7
Clinical Characteristics of Parkinson's Disease Developed from Essential Tremor. (28409750)
2017
8
Letter: Thalamotomy-Like Effects From Partial Removal of a Ventral Intermediate Nucleus Deep Brain Stimulator Lead in a Patient With Essential Tremor: Case Report. (28379503)
2017
9
Thalamic DBS with a constant-current device in essential tremor: AA controlled clinical trial. (28400200)
2017
10
Equivalence of cell survival data for radiation dose and thermal dose in ablative treatments: analysis applied to essential tremor thalamotomy by focused ultrasound and gamma knife. (28044461)
2017
11
Emotion modulation of the startle reflex in essential tremor: Blunted reactivity to unpleasant and pleasant pictures. (27887893)
2017
12
Probabilistic mapping of deep brain stimulation effects in essential tremor. (27981031)
2017
13
Topography of essential tremor. (28442304)
2017
14
Emerging strategies in the management of essential tremor. (28382111)
2017
15
Awareness of cognitive impairment in individuals with essential tremor. (28477687)
2017
16
Topiramate for essential tremor. (28409827)
2017
17
Mutation analysis of CHCHD2 gene in Chinese Han familial essential tremor patients and familial Parkinson's disease patients. (27814991)
2017
18
Support System to Improve Reading Activity in Parkinson's Disease and Essential Tremor Patients. (28467366)
2017
19
Focused Ultrasound for Essential Tremor: Review of the Evidence and Discussion of Current Hurdles. (28503363)
2017
20
Feasibility study: Effect of hand resistance exercise on handwriting in Parkinson's disease and essential tremor. (28389133)
2017
21
Non-invasive Brain Stimulation for Essential Tremor. (28373927)
2017
22
Action Tremor Asymmetry Profile Does Not Aggregate in Families with Essential Tremor. (28469594)
2017
23
Role of altered cerebello-thalamo-cortical network in the neurobiology of essential tremor. (28062908)
2017
24
Cognitive Dysfunction Is Associated with Greater Imbalance and Falls in Essential Tremor. (28469597)
2017
25
Obsessive compulsive personality disorder in Progressive Supranuclear Palsy, Multiple System Atrophy and Essential Tremor. (27364040)
2016
26
Cerebellar dysfunction in essential tremor. (27062434)
2016
27
SLC1A2 rs3794087 are associated with susceptibility to Parkinson's disease, but not essential tremor, amyotrophic lateral sclerosis or multiple system atrophy in a Chinese population. (27206883)
2016
28
Patients with essential tremor can have manual dexterity and attention deficits with no impairments in other cognitive functions. (26982989)
2016
29
A family study of DRD3 rs6280, SLC1A2 rs3794087 and MAPT rs1052553 variants in essential tremor. (27456607)
2016
30
Movement disorders: Novel genetic risk variants for essential tremor. (27811916)
2016
31
Deep Brain Stimulation Salvages a Flourishing Dental Practice: A Dentist with Essential Tremor Recounts his Experience. (27909628)
2016
32
Excitatory Amino acid transporter expression in the essential tremor dentate nucleus and cerebellar cortex: A postmortem study. (27624392)
2016
33
Precise stimulation location optimizes speech outcomes in essential tremor. (27595548)
2016
34
Nonlinear interactions in the thalamocortical loop in essential tremor: A model-based frequency domain analysis. (26987955)
2016
35
Genome-wide association study in essential tremor identifies three new loci. (27797806)
2016
36
A Trial of Focused Ultrasound Thalamotomy for Essential Tremor. (27959759)
2016
37
Development of method for quantifying essential tremor using a small optical device. (27058772)
2016
38
Functional Ability Improved in Essential Tremor by IncobotulinumtoxinA Injections Using Kinematically Determined Biomechanical Patterns - A New Future. (27101283)
2016
39
A Randomized Trial of Focused Ultrasound Thalamotomy for Essential Tremor. (27557301)
2016
40
Treatment of Medically Refractory Essential Tremor. (27557307)
2016
41
Agnosia for head tremor in essential tremor: prevalence and clinical correlates. (26877883)
2016
42
Cerebellar involvement in essential tremor with and without resting tremor: A Diffusion Tensor Imaging study. (27050442)
2016
43
A suggested minimum standard deep brain stimulation evaluation for essential tremor. (26944141)
2016
44
Time reproduction deficits in essential tremor patients. (27091412)
2016
45
Cannabinoid type 1 receptor antagonism ameliorates harmaline-induced essential tremor in rat. (27545646)
2016
46
Taking on Essential Tremor: New Tools and Approaches Offer patients Increased Treatment Options. (27187536)
2016
47
Current concepts of essential tremor. (27561441)
2016
48
Clinical validation of a precision electromagnetic tremor measurement system in participants receiving deep brain stimulation for essential tremor. (27511464)
2016
49
Immediate and Longitudinal Alterations of Functional Networks after Thalamotomy in Essential Tremor. (27822200)
2016
50
More Time with Tremor: The Experience of Essential Tremor Versus Parkinson's Disease Patients. (27430000)
2016

Variations for Essential Tremor

About this section

Expression for genes affiliated with Essential Tremor

About this section
Search GEO for disease gene expression data for Essential Tremor.

Pathways for genes affiliated with Essential Tremor

About this section

Pathways related to Essential Tremor according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.9SLC6A3, SNCA
29.0FMR1, LRRK2, SLC1A2, SNCA
39.0HTRA2, LRRK2, SLC6A3, SNCA

GO Terms for genes affiliated with Essential Tremor

About this section

Cellular components related to Essential Tremor according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1inclusion bodyGO:001623410.7LRRK2, SNCA
2growth coneGO:003042610.3FMR1, LRRK2, SNCA
3perikaryonGO:004320410.2FMR1, FUS, LRRK2
4polysomeGO:000584410.1FMR1, FUS
5neuron projectionGO:004300510.0FMR1, LRRK2, SLC6A3, TENM4
6neuronal cell bodyGO:004302510.0FUS, LRRK2, SLC6A3, SNCA
7axonGO:00304249.6FMR1, LRRK2, SLC1A2, SLC6A3, SNCA
8postsynapseGO:00987949.4FMR1, LRRK2, SNCA
9plasma membraneGO:00058867.3ANO3, DNAJC13, DRD3, FMR1, LRRK2, SLC1A2
10membraneGO:00160206.5ANO3, DNAJC13, DRD3, FMR1, HTRA2, LINGO2

Biological processes related to Essential Tremor according to GeneCards Suite gene sharing:

(show all 17)
idNameGO IDScoreTop Affiliating Genes
1prepulse inhibitionGO:006013410.6DRD3, SLC6A3
2behavioral response to cocaineGO:004814810.6DRD3, SNCA
3positive regulation of dopamine receptor signaling pathwayGO:006016110.6DRD3, LRRK2
4dopamine metabolic processGO:004241710.6DRD3, SNCA
5dopamine biosynthetic processGO:004241610.5SLC6A3, SNCA
6regulation of dopamine secretionGO:001405910.5DRD3, SNCA
7dopamine uptake involved in synaptic transmissionGO:005158310.5SLC6A3, SNCA
8regulation of neuron deathGO:190121410.5LRRK2, SNCA
9regulation of neurotransmitter secretionGO:004692810.4FMR1, SNCA
10response to cocaineGO:004222010.3DRD3, SLC6A3, SNCA
11regulation of locomotionGO:004001210.2DRD3, LRRK2, SNCA
12regulation of multicellular organism growthGO:004001410.2DRD3, HTRA2
13agingGO:00075689.9HTRA2, SLC6A3, SNCA
14synaptic transmission, dopaminergicGO:00019639.9DRD3, SNCA
15cellular response to oxidative stressGO:00345999.9HTRA2, LRRK2, SNCA
16negative regulation of neuron deathGO:19012159.9HTRA2, LRRK2, SNCA
17response to drugGO:00424939.5DRD3, SLC1A2, SLC6A3, SNCA

Molecular functions related to Essential Tremor according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1dopamine bindingGO:003524010.7DRD3, SLC6A3
2dynein complex bindingGO:007084010.4FMR1, SNCA
3microtubule bindingGO:00080179.4FMR1, LRRK2, SNCA
4identical protein bindingGO:00428029.0FMR1, FUS, HTRA2, LRRK2, SNCA

Sources for Essential Tremor

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet